Literature DB >> 24317633

Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia.

Maram T Basha1, Carlos Rodríguez, Des R Richardson, Manuel Martínez, Paul V Bernhardt.   

Abstract

The oxidation of oxyhemoglobin to methemoglobin has been found to be facilitated by low molecular weight iron(III) thiosemicarbazone complexes. This deleterious reaction, which produces hemoglobin protein units unable to bind dioxygen and occurs during the administration of iron chelators such as the well-known 3-aminopyridine-2-pyridinecarbaldehyde thiosemicarbazone (3-AP; Triapine), has been observed in the reaction with Fe(III) complexes of some members of the 3-AP structurally-related thiosemicarbazone ligands derived from di-2-pyridyl ketone (HDpxxT series). We have studied the kinetics of this oxidation reaction in vitro using human hemoglobin and found that the reaction proceeds with two distinct time-resolved steps. These have been associated with sequential oxidation of the two different oxyheme cofactors in the α and β protein chains. Unexpected steric and hydrogen-bonding effects on the Fe(III) complexes appear to be the responsible for the observed differences in the reaction rate across the series of HDpxxT ligand complexes used in this study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24317633     DOI: 10.1007/s00775-013-1070-9

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  47 in total

1.  Reciprocal effects in human hemoglobin: direct measurement of the dimer-tetramer association constant at partial oxygen saturation.

Authors:  R Valdes; L P Vickers; H R Halvorson; G K Ackers
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

2.  Spectral analysis of Fe(III)-complex reduction by hemoglobin: possible mechanisms of interaction.

Authors:  J P Harrington; R L Hicks
Journal:  Int J Biochem       Date:  1994-09

3.  Redox potentials of normal and SH(beta 93)-modified human hemoglobin. Effect of pH and D-glycerate 2,3-bisphosphate.

Authors:  R Santucci; F Ascoli; E Antonini
Journal:  Biochim Biophys Acta       Date:  1984-08-28

4.  Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.

Authors:  Patricia Quach; Elaine Gutierrez; Maram Talal Basha; Danuta S Kalinowski; Philip C Sharpe; David B Lovejoy; Paul V Bernhardt; Patric J Jansson; Des R Richardson
Journal:  Mol Pharmacol       Date:  2012-04-16       Impact factor: 4.436

Review 5.  Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia.

Authors:  Charles A Kunos; Tomas Radivoyevitch; Stephen T Ingalls; Charles L Hoppel
Journal:  Future Oncol       Date:  2012-02       Impact factor: 3.404

6.  Biphasic nature in the autoxidation reaction of human oxyhemoglobin.

Authors:  M Tsuruga; K Shikama
Journal:  Biochim Biophys Acta       Date:  1997-01-04

7.  Electrochemical Behavior of the Fe(III) Complexes of the Cyclic Hydroxamate Siderophores Alcaligin and Desferrioxamine E.

Authors:  Ivan Spasojevic; Sandra K. Armstrong; Timothy J. Brickman; Alvin L. Crumbliss
Journal:  Inorg Chem       Date:  1999-02-08       Impact factor: 5.165

8.  Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.

Authors:  Paul V Bernhardt; Philip C Sharpe; Mohammad Islam; David B Lovejoy; Danuta S Kalinowski; Des R Richardson
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

9.  Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

Authors:  Olatoyosi M Odenike; Richard A Larson; Devika Gajria; M Eileen Dolan; Shannon M Delaney; Theodore G Karrison; Mark J Ratain; Wendy Stock
Journal:  Invest New Drugs       Date:  2008-01-24       Impact factor: 3.850

10.  Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).

Authors:  Jennifer J Knox; Sebastien J Hotte; Christian Kollmannsberger; Eric Winquist; Bryn Fisher; Elizabeth A Eisenhauer
Journal:  Invest New Drugs       Date:  2007-03-28       Impact factor: 3.850

View more
  2 in total

1.  Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers.

Authors:  Charles A Kunos; Edward Chu; Della Makower; Andreas Kaubisch; Mario Sznol; Susan Percy Ivy
Journal:  Front Oncol       Date:  2017-04-04       Impact factor: 6.244

2.  Liposomal formulations of anticancer copper(II) thiosemicarbazone complexes.

Authors:  Marlene Mathuber; Sonja Hager; Bernhard K Keppler; Petra Heffeter; Christian R Kowol
Journal:  Dalton Trans       Date:  2021-11-16       Impact factor: 4.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.